Finasteride

Finasteride, sold under the brand names Proscar and Propecia among others, is a medication used for the treatment of benign prostatic hyperplasia (BPH) and male pattern baldness (MPB). It is a type II and type III 5α-reductase inhibitor; 5α-reductase, an enzyme, converts testosterone to dihydrotestosterone (DHT).

Medical uses

Benign prostatic hyperplasia

Physicians use finasteride for the treatment of BPH, informally known as an enlarged prostate. Finasteride may improve the symptoms associated with BPH such as difficulty urinating, getting up during the night to urinate, hesitation at the start of urination, and decreased urinary flow. It provides less symptomatic relief than alpha-1 blockers such as tamsulosin and symptomatic relief is slower in onset (six months or more of treatment with finasteride may be required to determine the therapeutic results of treatment). Symptomatic benefits are mainly seen in those with prostate volume > 40 cm3. In long-term studies finasteride but not alpha-1 inhibitors reduce the risk of acute urinary retention (−57% at 4 years) and the need for surgery (−54% at 4 years). If the drug is discontinued, any therapeutic benefits reverse within about 6–8 months.

Male pattern baldness

Finasteride is used to treat male pattern hair loss (androgenetic alopecia) in men only. Treatment slows further hair loss and provides about 30% improvement in hair loss after six months of treatment, with effectiveness only persisting as long as the drug is taken.

Off-label uses

Finasteride is sometimes used in hormone replacement therapy for transgender women in combination with a form of estrogen due to its antiandrogen properties. However, little clinical research of finasteride use for this purpose has been conducted and evidence of efficacy is limited.

Basic information:

Product Name: Finasteride, proscar, propecia

CAS  No: 98319-26-7
Molecular Formula: C23H36N2O2
Molecular Weight; 372.55

Standard: GMP /USP34/EP7

Usage of Finasteride :1) Use for treatment of hair loss

 2) For the treatment of benign prostatic hyperplasia, enlarged prostate shrink, improve urinary flow and improvementof benign prostatic hyperplasia caused symptoms.

Certificate of analysis for Finasteride:

TEST	SPECIFICATIONS	RESULTS
Appearance	White or almost white crystalline powder. Melts at about 257°C	Complies
Assay (HPLC, based on drying)	98.5% ~ 101.0% calculated on anhydrous basis	99.55%
Identification  Infrared Absorption Retention time	Corresponds to spectrum of USP Finasteride RS Retention time of major peak of Assay preparation corresponds to USP Finasteride RS preparation	Corresponds to spectrum of USP Finasteride RS Retention time of major peak of Assay preparation corresponds to USP Finasteride RS preparation
Specific rotation	-56.0°~ -60.0°	-57.5°
Melting Point	Melts at about 257°	complies
Solubility	Free soluble in Chloroform and in alcohol,very slightly soluble in water	Complies
Water (Method I)	≤0.3%	0.16%
Residue on ignition	≤0.1%	0.07%
Heavy metals (Method II)	≤10 ppm	Complies
Chromatographic purity	Single largest impurity: ≤0.5%	0.09%
	Total impurities: ≤1.0%	0.28%
Particle size	100% < 30 micron	Complies
	90% < 25 micron	Complies
Conclusion	The test product complies with the requirements of USP32.

Packaging & Shipping：

Packaging Detail: 1. 10,50g,100g,500g,1kg in aluminum foil bags & 25kg/barrel.

                          2. The packaging can be on request

Delivery Detail:  5-7days for regular shipping

                         7-15days if shipping get delayed

my contact infomation is:

Email: cloris_2016@tuskwei.com or

bettytuskwei@yahoo.com

Skype: betty_3451

Website: http://www.tuskwei.net/

Notice: This product is only suitable for laboratory use, or the use of animals. It can not be used directly on the human body